Oakrum Pharma Announces the Launch of Pyrimethamine 25mg Tablets in the United States

Wednesday, March 11, 2020 Drug News
Email Print This Page Comment bookmark
Font : A-A+

ST. LOUIS, March 11, 2020 /PRNewswire/ -- Oakrum Pharma, LLC ("Oakrum") announced today the launch and commercial distribution of pyrimethamine 25mg tablets in the United States.

With the launch of pyrimethamine 25mg tablets today, Oakrum expects to be the first to bring generic pyrimethamine 25mg tablets, as an authorized generic, to the market.  Oakrum intends to distribute this product through Optime Care Inc., a St. Louis-based, nationally licensed, specialty pharmacy and wholesale distributor.  Oakrum selected Optime Care as its partner for this product because of Optime Care's commitment to provide patients and their caregivers with dedicated programs and services in support of this important drug. 

About Oakrum Pharma, LLC 

Oakrum Pharma, LLC is a privately-owned biopharmaceutical company focusing on development and commercialization of affordable drug therapies.  For more information, visit www.oakrumpharma.com.  

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Oakrum are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Oakrum intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Oakrum's actual results to be materially different from its historical results or from any results expressed or implied by said statements. Oakrum's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions and the need for regulatory approvals, Oakrum's ability to fund development of its technology and to successfully complete clinical trials, the length of time and costs required to complete clinical trials and to submit applications for regulatory approvals, products developed by competing companies, commercial acceptance of Oakrum's products, and other factors. Oakrum is not responsible for updating events occurring after the date of this press release.

 

Cision View original content:http://www.prnewswire.com/news-releases/oakrum-pharma-announces-the-launch-of-pyrimethamine-25mg-tablets-in-the-united-states-301021098.html

SOURCE Oakrum Pharma, LLC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store